Developer docs
API playgroundTry for free, no card

Search company profiles

Maze Therapeutics

Full company profile

uuid00000ik

Namestring
Maze Therapeutics
Legal namestring
Maze Therapeutics, Inc.
Websiteurl
mazetx.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Maze Therapeutics is a clinical-stage biopharmaceutical company founded in summer 2018 and headquartered in South San Francisco, California. The company is developing oral small-molecule precision medicines for renal, cardiovascular, and metabolic diseases, with a current focus on three clinical-stage programs: MZE829, an oral APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease (AMKD); MZE782, an oral SLC6A19 inhibitor in Phase 2 for both chronic kidney disease (CKD) and phenylketonuria (PKU); and S-606001 (formerly MZE001), an oral GYS1 inhibitor for late-onset Pompe disease that was licensed to Shionogi in 2024 and is now in Phase 2 under Shionogi's Esprit trial. Maze's discovery engine is its proprietary Maze Compass™ Platform, which applies variant functionalization — systematically identifying naturally occurring protective genetic variants in large population datasets and designing small molecules that mimic their biological effects — to de-risk target selection and predict safety before clinical development. The company went public on NASDAQ under ticker MAZE in 2025, with its stock appreciating 157% in its first year.

The business model is that of a clinical-stage biotech with no approved products and no recurring revenue. The single material revenue event to date is a $150 million upfront payment from the 2024 Shionogi licensing agreement for S-606001, with the broader deal potentially worth up to $735 million in upfront and milestones plus royalties. Future revenue is expected from a mix of direct commercialization of MZE829 and MZE782 (likely via specialty pharmacy and nephrology-focused distribution upon approval) and additional out-licensing transactions for non-core assets. The company serves genetically defined patient populations — approximately 1 million U.S. patients with AMKD, 37 million U.S. CKD patients, and roughly 60,000 PKU patients worldwide — through traditional pharmaceutical development executed via clinical trials, scientific publications, and investor/scientific conferences.

Maze has raised approximately $715 million cumulatively since inception across venture rounds (a $190M round led by Matrix Capital in 2022, a $115M Series D in 2024), a 2025 IPO, a $150M oversubscribed private placement in September 2025, and a $150M registered offering in April 2026. Cash position stood at $360 million as of Q4 2025, with the post-IPO raise explicitly intended to extend operational runway into 2029. The leadership team is anchored by CEO Jason Coloma (former Third Rock Ventures operating partner) and Chairman Hervé Hoppenot (former CEO of Incyte), with a board that includes Neil Kumar (BridgeBio Pharma CEO), Richard Scheller (former 23andMe CSO), and Daniel K. Spiegelman (former BioMarin CFO). The company had a net loss of $131.1 million for full year 2025 against zero product revenue.

Short descriptiontext

Maze Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule precision medicines for kidney and metabolic diseases, using its proprietary Compass Platform to translate protective genetic variants into therapies targeting APOL1-mediated kidney disease, chronic kidney disease, phenylketonuria, and Pompe disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision medicine development, small molecule therapeutics, genetic variant drug discovery, kidney disease treatments, clinical-stage biopharmaceutical
Industry3 codes
PRIMARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Precision Medicine Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Revenue
TypeOne Time License
Description

Currently pre-revenue clinical-stage company with no approved products. All revenue in 2024 came from a $150 million upfront payment from licensing agreement with Shionogi for MZE001. Future revenue expected from drug approvals and commercialization.

biospace.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Licensing agreement with Shionogi provides potential future milestone payments for development and regulatory achievements for MZE001 (S-606001) in Pompe disease. Deal potentially worth up to $735 million in upfront and milestone payments.

ir.mazetx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Maze Compass
Description

Proprietary purpose-built platform to understand and integrate variant functionalization into drug development

mazetx.com
Core offering1 text field

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, and metabolic diseases. The company leverages its proprietary Maze Compass™ Platform, which applies variant functionalization to translate human genetic insights into targeted therapies. Its pipeline includes three clinical-stage programs: MZE829 (APOL1 inhibitor for APOL1-mediated kidney disease), MZE782 (SLC6A19 inhibitor for chronic kidney disease and phenylketonuria), and MZE001 (GYS1 inhibitor for Pompe disease, licensed to Shionogi).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 35.6% mean uACR reduction at week 12 for MZE829 in broad AMKD patients
+4 more records
Product overview1 text field

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases. The company's portfolio consists of three clinical-stage programs: MZE829 (Phase 2, APOL1-mediated kidney disease), MZE782 (Phase 2, CKD and PKU), and MZE001 (licensed to Shionogi, Phase 2 for Pompe disease). The Maze Compass™ Platform underlies the company's drug discovery approach, leveraging variant functionalization to identify therapeutic targets based on genetic insights.

Product and service4 records
1MZE829
CategoryClinical-stage drug candidate
Description

Oral small molecule inhibitor of APOL1 being evaluated in Phase 2 trials for the treatment of APOL1-mediated kidney disease (AMKD) and focal segmental glomerulosclerosis (FSGS). Targets patients with high-risk APOL1 gene variants, most prevalent in people of West African ancestry.

2MZE782
CategoryClinical-stage drug candidate
Description

Investigational potent, selective oral inhibitor of SLC6A19 (sodium-dependent neutral amino acid transporter) being developed for both chronic kidney disease (CKD) and phenylketonuria (PKU). Provides a genotype-agnostic approach for PKU and a complementary mechanism for CKD.

3MZE001 (S-606001)
CategoryClinical-stage drug candidate (licensed)
Description

Oral glycogen synthase 1 (GYS1) inhibitor developed as a substrate reduction therapy for Pompe disease, addressing limitations of enzyme replacement therapy by reducing glycogen production. Licensed exclusively to Shionogi & Co. for worldwide development and commercialization.

4Maze Compass™ Platform
CategoryDrug discovery platform
Description

Proprietary purpose-built drug discovery platform leveraging variant functionalization to understand and integrate genetic insights into each stage of drug development. Used to identify protective genetic variants and design precision medicines that mimic their effects.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-02-19
Description

Zifo and Maze Therapeutics partnered to provide AI-powered scientific workflows for managing and scaling biobank data to advance precision medicine research. The platform integrates genetic and phenotypic datasets into a unified system capable of rendering summary statistics in under five seconds. Maze uses Zifo's enterprise informatics platform to process data from UK Biobank and All of Us Research Program, aiming to accelerate target discovery and reduce manual effort and data fragmentation.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Collaboration on pharmacokinetic/pharmacodynamic modeling for MZE782 treatment in phenylketonuria. Published research in March 2026 at ASCPT conference presenting mechanistic PK/PD model translating healthy volunteer data to PKU patients.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-01
Description

Shionogi acquired exclusive worldwide rights to S-606001 (formerly MZE001) from Maze Therapeutics in 2024 in a deal potentially worth up to $735 million in upfront and milestone payments. Shionogi is conducting the global Phase 2 Esprit trial evaluating S-606001 as an oral substrate reduction therapy for late-onset Pompe disease. The drug received rare pediatric disease designation from FDA in 2025 and Orphan Drug Designation in 2022.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Collaboration to develop novel glycogen synthase 1 (GYS1) therapies as strategic advancement in addressing root causes of glycogen accumulation in Pompe disease patients. Note: This appears in market research reporting about Nexviazyme; Maze's MZE001 is a separate GYS1 inhibitor program licensed to Shionogi.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty biopharma with established rare-disease franchises and a precision-medicine, genetics-driven discovery approach; comparable as a publicly traded rare/orphan disease developer with multiple wholly owned programs advancing through clinical development.

TypeDirect peer
Description

Genetic-medicine company developing therapies for diseases caused by genetic variants, with a meaningful focus on renal and cardiovascular diseases (e.g., acoramidis for ATTR-CM, infigratinib for ADPKD); directly comparable as a fellow genetically driven precision-medicine biotech and shares a board connection (Neil Kumar).

TypeDirect peer
Description

Late-stage rare-disease company with approved Filspari (sparsentan) for IgA nephropathy and an FSGS program, directly competing with Maze in the genetically defined kidney disease space, particularly the FSGS subgroup where MZE829 showed 61.8% uACR reduction.

TypeBroad incumbent
Description

Established rare-disease specialist with multiple approved orphan therapies across metabolic and genetic conditions; comparable business model and regulatory/commercial expertise relevant as Maze builds out its own rare-disease launch capabilities.

TypeEmerging player
Description

Genetic-medicine platform company developing antisense oligonucleotide therapies for rare and serious diseases; shares the precision-medicine ethos and rare-disease focus, with multiple wholly owned and partnered clinical assets.

TypeBroad incumbent
Description

Genetic-medicine company pioneering RNA interference (RNAi) therapeutics with multiple approved rare-disease products; comparable as a platform-based precision-medicine company translating genetic insights into approved therapies, though using a different modality.

TypeBroad incumbent
Description

Large-cap biopharma with strong genetics-driven discovery (Regeneron Genetics Center) and rare-disease programs, including antibody-based therapies for genetic conditions; relevant as a mature genetic-medicine platform comparable to Maze Compass.

TypeDirect peer
Description

Pre-acquisition, Chinook was a clinical-stage nephrology-focused biotech developing precision medicines for rare kidney diseases (IgA nephropathy, ADPKD), acquired by Novartis in 2023 for ~$3.5B; directly comparable as a kidney-focused precision-medicine platform validated by a major strategic transaction.

TypeEmerging player
Description

Clinical-stage rare-disease biotech developing precision therapies for hematologic disorders with genetic drivers; comparable as an emerging, publicly traded platform-based rare-disease company with multiple clinical assets and similar size/stage profile.

TypeEmerging player
Description

Clinical-stage rare-disease company developing oral small-molecule precision therapies for endocrine disorders; comparable as a clinical-stage rare/orphan disease biotech advancing multiple wholly owned programs toward approval.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Maze Therapeutics

Clinical-Stage Precision Medicine Pharmaceuticalsmazetx.com

Maze Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule precision medicines for kidney and metabolic diseases, using its proprietary Compass Platform to translate protective genetic variants into therapies targeting APOL1-mediated kidney disease, chronic kidney disease, phenylketonuria, and Pompe disease.

What Maze Therapeutics does

Maze Therapeutics is a clinical-stage biopharmaceutical company founded in summer 2018 and headquartered in South San Francisco, California. The company is developing oral small-molecule precision medicines for renal, cardiovascular, and metabolic diseases, with a current focus on three clinical-stage programs: MZE829, an oral APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease (AMKD); MZE782, an oral SLC6A19 inhibitor in Phase 2 for both chronic kidney disease (CKD) and phenylketonuria (PKU); and S-606001 (formerly MZE001), an oral GYS1 inhibitor for late-onset Pompe disease that was licensed to Shionogi in 2024 and is now in Phase 2 under Shionogi's Esprit trial. Maze's discovery engine is its proprietary Maze Compass™ Platform, which applies variant functionalization — systematically identifying naturally occurring protective genetic variants in large population datasets and designing small molecules that mimic their biological effects — to de-risk target selection and predict safety before clinical development. The company went public on NASDAQ under ticker MAZE in 2025, with its stock appreciating 157% in its first year.

The business model is that of a clinical-stage biotech with no approved products and no recurring revenue. The single material revenue event to date is a $150 million upfront payment from the 2024 Shionogi licensing agreement for S-606001, with the broader deal potentially worth up to $735 million in upfront and milestones plus royalties. Future revenue is expected from a mix of direct commercialization of MZE829 and MZE782 (likely via specialty pharmacy and nephrology-focused distribution upon approval) and additional out-licensing transactions for non-core assets. The company serves genetically defined patient populations — approximately 1 million U.S. patients with AMKD, 37 million U.S. CKD patients, and roughly 60,000 PKU patients worldwide — through traditional pharmaceutical development executed via clinical trials, scientific publications, and investor/scientific conferences.

Maze has raised approximately $715 million cumulatively since inception across venture rounds (a $190M round led by Matrix Capital in 2022, a $115M Series D in 2024), a 2025 IPO, a $150M oversubscribed private placement in September 2025, and a $150M registered offering in April 2026. Cash position stood at $360 million as of Q4 2025, with the post-IPO raise explicitly intended to extend operational runway into 2029. The leadership team is anchored by CEO Jason Coloma (former Third Rock Ventures operating partner) and Chairman Hervé Hoppenot (former CEO of Incyte), with a board that includes Neil Kumar (BridgeBio Pharma CEO), Richard Scheller (former 23andMe CSO), and Daniel K. Spiegelman (former BioMarin CFO). The company had a net loss of $131.1 million for full year 2025 against zero product revenue.

Maze Therapeutics firmographics

Firmographics
Name
Maze Therapeutics
Legal name
Maze Therapeutics, Inc.
Website
https://mazetx.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Maze Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule precision medicines for kidney and metabolic diseases, using its proprietary Compass Platform to translate protective genetic variants into therapies targeting APOL1-mediated kidney disease, chronic kidney disease, phenylketonuria, and Pompe disease.
Ownership category
akta.pro rank

Maze Therapeutics industry classification

Industry
Product category
Clinical-Stage Precision Medicine Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision medicine development
  • Small molecule therapeutics
  • Genetic variant drug discovery
  • Kidney disease treatments
  • Clinical-stage biopharmaceutical

Where Maze Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Maze Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Product Revenue: Currently pre-revenue clinical-stage company with no approved products. All revenue in 2024 came from a $150 million upfront payment from licensing agreement with Shionogi for MZE001. Future revenue expected from drug approvals and commercialization.
  2. Licensing and Milestone Payments: Licensing agreement with Shionogi provides potential future milestone payments for development and regulatory achievements for MZE001 (S-606001) in Pompe disease. Deal potentially worth up to $735 million in upfront and milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Maze Therapeutics product offering

Product offering

Core offering

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, and metabolic diseases. The company leverages its proprietary Maze Compass™ Platform, which applies variant functionalization to translate human genetic insights into targeted therapies. Its pipeline includes three clinical-stage programs: MZE829 (APOL1 inhibitor for APOL1-mediated kidney disease), MZE782 (SLC6A19 inhibitor for chronic kidney disease and phenylketonuria), and MZE001 (GYS1 inhibitor for Pompe disease, licensed to Shionogi).

Product overview

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases. The company's portfolio consists of three clinical-stage programs: MZE829 (Phase 2, APOL1-mediated kidney disease), MZE782 (Phase 2, CKD and PKU), and MZE001 (licensed to Shionogi, Phase 2 for Pompe disease). The Maze Compass™ Platform underlies the company's drug discovery approach, leveraging variant functionalization to identify therapeutic targets based on genetic insights.

Differentiator

Problem solved

Functional benefit

Brands

  • Maze Compass: Proprietary purpose-built platform to understand and integrate variant functionalization into drug development

Products and services

  • MZE829 Oral small molecule inhibitor of APOL1 being evaluated in Phase 2 trials for the treatment of APOL1-mediated kidney disease (AMKD) and focal segmental glomerulosclerosis (FSGS). Targets patients with high-risk APOL1 gene variants, most prevalent in people of West African ancestry.
  • MZE782 Investigational potent, selective oral inhibitor of SLC6A19 (sodium-dependent neutral amino acid transporter) being developed for both chronic kidney disease (CKD) and phenylketonuria (PKU). Provides a genotype-agnostic approach for PKU and a complementary mechanism for CKD.
  • MZE001 (S-606001) Oral glycogen synthase 1 (GYS1) inhibitor developed as a substrate reduction therapy for Pompe disease, addressing limitations of enzyme replacement therapy by reducing glycogen production. Licensed exclusively to Shionogi & Co. for worldwide development and commercialization.
  • Maze Compass™ Platform Proprietary purpose-built drug discovery platform leveraging variant functionalization to understand and integrate genetic insights into each stage of drug development. Used to identify protective genetic variants and design precision medicines that mimic their effects.

Quantifiable outcome

  • 35.6% mean uACR reduction at week 12 for MZE829 in broad AMKD patients
  • +4 more outcomes

Companies that use Maze Therapeutics

Customer profile

Segments4 records

Ideal customer profiles4 records

Maze Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Maze Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered strategic, minor and core.

  • Zifo TechnologiesstrategicTechnology or Integration · 19 February 2026Zifo and Maze Therapeutics partnered to provide AI-powered scientific workflows for managing and scaling biobank data to advance precision medicine research. The platform integrates genetic and phenotypic datasets into a unified system capable of rendering summary statistics in under five seconds. Maze uses Zifo's enterprise informatics platform to process data from UK Biobank and All of Us Research Program, aiming to accelerate target discovery and reduce manual effort and data fragmentation.
  • Certara, Inc.minorStrategic or Co-development Partner · 18 February 2026Collaboration on pharmacokinetic/pharmacodynamic modeling for MZE782 treatment in phenylketonuria. Published research in March 2026 at ASCPT conference presenting mechanistic PK/PD model translating healthy volunteer data to PKU patients.
  • Shionogi & Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2024Shionogi acquired exclusive worldwide rights to S-606001 (formerly MZE001) from Maze Therapeutics in 2024 in a deal potentially worth up to $735 million in upfront and milestone payments. Shionogi is conducting the global Phase 2 Esprit trial evaluating S-606001 as an oral substrate reduction therapy for late-onset Pompe disease. The drug received rare pediatric disease designation from FDA in 2025 and Orphan Drug Designation in 2022.
  • SanofiminorStrategic or Co-development Partner · 1 January 2023Collaboration to develop novel glycogen synthase 1 (GYS1) therapies as strategic advancement in addressing root causes of glycogen accumulation in Pompe disease patients. Note: This appears in market research reporting about Nexviazyme; Maze's MZE001 is a separate GYS1 inhibitor program licensed to Shionogi.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Maze Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Vertex Pharmaceuticals: Specialty biopharma with established rare-disease franchises and a precision-medicine, genetics-driven discovery approach; comparable as a publicly traded rare/orphan disease developer with multiple wholly owned programs advancing through clinical development.
  • BioMarin Pharmaceutical: Established rare-disease specialist with multiple approved orphan therapies across metabolic and genetic conditions; comparable business model and regulatory/commercial expertise relevant as Maze builds out its own rare-disease launch capabilities.
  • Alnylam Pharmaceuticals: Genetic-medicine company pioneering RNA interference (RNAi) therapeutics with multiple approved rare-disease products; comparable as a platform-based precision-medicine company translating genetic insights into approved therapies, though using a different modality.
  • Regeneron Pharmaceuticals: Large-cap biopharma with strong genetics-driven discovery (Regeneron Genetics Center) and rare-disease programs, including antibody-based therapies for genetic conditions; relevant as a mature genetic-medicine platform comparable to Maze Compass.

Direct peers

  • BridgeBio Pharma: Genetic-medicine company developing therapies for diseases caused by genetic variants, with a meaningful focus on renal and cardiovascular diseases (e.g., acoramidis for ATTR-CM, infigratinib for ADPKD); directly comparable as a fellow genetically driven precision-medicine biotech and shares a board connection (Neil Kumar).
  • Travere Therapeutics: Late-stage rare-disease company with approved Filspari (sparsentan) for IgA nephropathy and an FSGS program, directly competing with Maze in the genetically defined kidney disease space, particularly the FSGS subgroup where MZE829 showed 61.8% uACR reduction.
  • Chinook Therapeutics: Pre-acquisition, Chinook was a clinical-stage nephrology-focused biotech developing precision medicines for rare kidney diseases (IgA nephropathy, ADPKD), acquired by Novartis in 2023 for ~$3.5B; directly comparable as a kidney-focused precision-medicine platform validated by a major strategic transaction.

Emerging players

  • Ionis Pharmaceuticals: Genetic-medicine platform company developing antisense oligonucleotide therapies for rare and serious diseases; shares the precision-medicine ethos and rare-disease focus, with multiple wholly owned and partnered clinical assets.
  • Disc Medicine: Clinical-stage rare-disease biotech developing precision therapies for hematologic disorders with genetic drivers; comparable as an emerging, publicly traded platform-based rare-disease company with multiple clinical assets and similar size/stage profile.
  • Crinetics Pharmaceuticals: Clinical-stage rare-disease company developing oral small-molecule precision therapies for endocrine disorders; comparable as a clinical-stage rare/orphan disease biotech advancing multiple wholly owned programs toward approval.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Maze Therapeutics social profiles

Digital presence

Maze Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Maze Therapeutics leadership team

Management profile

Number of profiles

Profiles16 records

Maze Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Maze Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maze Therapeutics

What does Maze Therapeutics do?

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, and metabolic diseases. The company leverages its proprietary Maze Compass™ Platform, which applies variant functionalization to translate human genetic insights into targeted therapies. Its pipeline includes three clinical-stage programs: MZE829 (APOL1 inhibitor for APOL1-mediated kidney disease), MZE782 (SLC6A19 inhibitor for chronic kidney disease and phenylketonuria), and MZE001 (GYS1 inhibitor for Pompe disease, licensed to Shionogi).

Is Maze Therapeutics a public or private company?

Maze Therapeutics is a public company. It is classified as public and is currently operating.

When was Maze Therapeutics founded?

Maze Therapeutics was founded in 2018. It employs 101 to 250 people.

Where is Maze Therapeutics based?

Maze Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Maze Therapeutics make money?

Two revenue lines are on record. Product Revenue is the primary driver. The others are licensing and Milestone Payments.

Who are Maze Therapeutics's main competitors?

Broad incumbents on record are Vertex Pharmaceuticals, BioMarin Pharmaceutical, Alnylam Pharmaceuticals and Regeneron Pharmaceuticals. Direct peers are BridgeBio Pharma, Travere Therapeutics and Chinook Therapeutics. Emerging players are Ionis Pharmaceuticals, Disc Medicine and Crinetics Pharmaceuticals.

Does Maze Therapeutics have an API?

No public API is recorded for Maze Therapeutics.

What industry is Maze Therapeutics in?

Maze Therapeutics's product category is Clinical-Stage Precision Medicine Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAI, Rare Renal & Nephrology Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMAZE: Three 2027 clinical catalysts are backed by cash runway into 2029MAZE's APOL1 Phase II HORIZON enrollment is complete, with data expected in early 2027 and a subsequent study planned that year. PKU data are expected in 2027, and a CKD Phase II study is planned for 2027. The company's cash runway extends into 2029.Investing.comMaze Therapeutics at Jefferies Global Healthcare Conference: pipeline gainsMaze Therapeutics presented its clinical pipeline at the Jefferies Global Healthcare Conference, highlighting progress in kidney disease and metabolic disorders. The company said its cash runway extends to 2029, with Phase II enrollment completed for its lead APOL1 inhibitor MZE829, which showed over 50% response and 30% UACR reduction. It plans pivotal studies in 2027.Simply Wall StMaze Therapeutics (MAZE) Stock Looks Pricey As Phase 2 Plans AdvanceMaze Therapeutics' stock rose 35.4% over the past month, trading at a 4.6x price-to-book ratio versus the pharmaceuticals industry average of 1.9x. The company holds $477 million in cash, which management expects to fund operations for several years. The valuation premium reflects market expectations of future trial outcomes.Simply Wall StMaze Therapeutics (MAZE) Reports Q3 Loss As Investors Weigh Whether Undervaluation Still HoldsMaze Therapeutics reported a Q3 net loss of $47.97 million and a basic loss per share of $0.79. The stock trades at $36.73, below the analyst consensus fair value of $62.55, with a 1-year total shareholder return of 15.36%.TradingViewJP Morgan maintains Maze Therapeutics at Overweight, lowers price target to $51 from $53JP Morgan maintained Maze Therapeutics at Overweight and lowered its price target to $51 from $53. The target implies a 43.9% upside from the Nov 10 close of $35.45.Defense WorldMaze Therapeutics (NASDAQ:MAZE) Given New $49.00 Price Target at WedbushWedbush raised its price target on Maze Therapeutics to $49 from $48, keeping an outperform rating. The stock opened at $35.45, and analysts have an average rating of Buy with a $64.55 target. The company reported a loss of $0.79 per share for the quarter.American Banking and Market News17,604 Maze Therapeutics, Inc. $MAZE Shares Bought by Alps Advisors Inc.Alps Advisors increased its stake in Maze Therapeutics by 31.5% in Q3, buying 17,604 shares. Insiders sold 192,991 shares over the past 90 days, and the stock opened at $35.45. Analysts have a consensus Buy rating with an average target of $64.55.Investing.comMaze Therapeutics at Guggenheim conference: enrollment beats guideMaze Therapeutics reported at the Guggenheim conference that its lead APOL1 kidney study enrolled over 50 patients, exceeding the 30-45 target. The company said its balance sheet funds data readouts through 2027, with PKU and CKD programs advancing. Management cited faster enrollment as a confidence booster for Phase III.Business & FinancialMaze Therapeutics To Participate In Upcoming Investor ConferencesMaze Therapeutics will present at three investor conferences in November and December 2026, including a Guggenheim fireside chat, a Jefferies presentation, and an Evercore chat. The company's pipeline is led by MZE829, an APOL1 inhibitor in Phase 2 for kidney disease, and MZE782, a SLC6A19 inhibitor for PKU and CKD.Stock TitanMaze Therapeutics to Participate in 3 Investor ConferencesMaze Therapeutics announced CEO Jason Coloma will participate in three investor conferences in November and December 2026. The events include a Guggenheim Healthcare Innovation Conference, a Jefferies Global Healthcare Conference in London, and an Evercore Healthcare Conference, with live webcasts available on the company's website.